Elevance Health Inc. (NYSE:ELV) is considered one of the most undervalued large cap stocks to invest in. Barclays and Guggenheim recently lowered price targets, while Deutsche Bank raised its target to $332. UBS also lowered their target to $400, all with varying ratings.

The company operates in the US as a health benefits company with four segments. While ELV shows potential as an investment, other AI stocks may offer greater upside potential. Insider Monkey suggests considering other AI stocks for investment opportunities.

15 States with the Best Healthcare in the US. Insider Monkey offers insights into potential investments in the AI sector. Disclosure: None. This article is originally published at Insider Monkey.

Read more at Yahoo Finance: Barclays Adjusts Elevance Health (ELV) PT to $393 While Maintaining Overweight Rating